95% healing in less than 2 months achieved with ReCell® for
explosion patient with 70% burn

Leading EU hospital incorporating ReCell® technology into
general protocol in Burns Unit

Various findings from top clinicians who presented at the REPAIR
session at Avita Medical's 4th Annual Skin Regeneration Symposium
(SRS) showed that the company's ReCell® regenerative skin
technology offers important advantages in patient recovery and
quality of life for the treatment of burns.

The burns-focused session during the event held at Cambridge
University was attended by some 140 clinicians and researchers with
an interest in the company's regenerative medicine approach. Many
of the presentations explored instances where skin grafting could
not be deployed as large body surface burns left few donor sites.
In these cases, ReCell® provided a strong alternative, the most
notable cases coming from Taiwan, where ReCell® was deployed
following the June 2015 Taipei Waterpark disaster, that left 15
people dead amongst the 499 people injured, with burns covering an
average of 43% of body surface area in the total group.

"By using early and aggressive surgical intervention, we were
able to treat over 60 patients in our hospital, with no
fatalities," said Dr Hung-Hui Lu, of the Burns Service of Taiwan.
"ReCell® was the perfect tool for severe and moderate burn
patients -- it was immediately available, enabled us to use smaller
donor sites and demonstrated faster epithelialisation. During
follow-up we have seen minimal scarring and contracture."

Under the FDA's Compassionate Use program, US burns specialist
Dr James H Holmes IV, MD FACS, Medical Director of the Burn Center
at Wake Forest Baptist Medical Center, North Carolina, USA has been
able to use ReCell® in a number of very serious burns cases,
including severe traffic accidents and extensive burns resulting
from explosions. "In our center, using the treatment has already
reduced mortality -- two years ago a patient with 90% would not
have been resuscitated." He also emphasized the additional benefit
of the concomitant treatment of donor sites, ensuring rapid
re-epithelialization and significant reduction in pain.

"I feel that pain reduction is a component of this treatment
which will have a big impact," added Dr Holmes. The issue of pain
reduction as a consequence of treatment with ReCell was echoed in
the findings presented by a number of speakers, as was a reduction
in itching.

Long-term outcomes were explored by Dr Elliott Cochrane, from
Pinderfields Hospital UK, who presented data on the use of
ReCell® in paediatric partial thickness scalds, where the
skin's epidermis and the dermis are damaged. His group of
researchers treated 100 children with 4 standard-of-care routes,
including ReCell® alone, or in conjunction with special
dressings. When following up the group 4 years later, they found
that the ReCell®-treated group had reduced-scarring and better
outcomes compared to other groups, which he believes now warrants
further investigation.

"A third of the annual 250,000 burn injuries in the UK are
paediatric, with scalds attributable for 65%," he said. "Over four
years, we have found that with ReCell® there was a low
incidence of scarring, when used with biosynthetic skin dressings
as standard-of-care, in addition to a reduction of itching,
significantly contributing to our patients' speed of recovery and
quality of life."

Knowing when and where ReCell® can offer advantages is
important. Having treated more than 100 cases with ReCell® over
the past seven years, Miss Isabel Jones, Clinical Lead for the
Burns Service at the NHS Chelsea and Westminster Hospital, stated:
"12 of the 15 cases of facial burns we have treated were healed
within four weeks. We are now integrating ReCell® into our
standard-of-care protocols."

"It's down to meticulous technique to get a good outcome with
ReCell®," stated Miss Alexandra Murray, Consultant Plastic and
Burns Surgeon and Clinical Lead for Burns at Stoke Mandeville
Hospital, UK, rounding off the session. Sharing her experiences of
using ReCell® in conjunction with a skin substitute in major
burns and complex soft tissue loss in over 400 cases, she
highlighted: "We had a case of a patient with burns on 70% of their
skin following an explosion. We saw 95% healing in 55 days, and two
years later the patient is fully back to work and able to
drive."

ABOUT THE 4TH ANNUAL SKIN REGENERATION SYMPOSIUM

140 experts from around the world are attending the 4th Annual
Skin Regeneration Symposium (SRS), which explores the latest
advancements in skin repair, regeneration and restoration and the
impact this has on patients. Keynote presentations are being
delivered by international experts from the fields of burns,
trauma, chronic wounds and aesthetics during the two-day session at
the University of Cambridge's Moller Centre, April 12-13.

The educational event, hosted by Avita, provides a forum to
showcase research and present robust clinical evidence of Avita's
pioneering ReCell® technology, supporting Avita's
commercialization drive, by providing the data required by medical
professionals and regulatory authorities, as well as drawing from
Avita's clinical bibliography of more than 60 abstracts and
peer-reviewed publications. In recent months, the Company has
published positive data from randomized trials in the areas of
pigmentation and venous leg ulcers, while an FDA-approval trial in
burns has just completed enrollment.

ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for
the treatment of a broad range of wounds, scars and skin defects.
Avita's patented and proprietary collection and application
technology provides innovative treatment solutions derived from a
patient's own skin. The Company's regenerative product portfolio
includes ReCell® for burns aimed at plastic reconstructive
procedures, ReGenerCell™ for chronic wounds and
ReNovaCell™ of restoration of pigmentation and cosmesis.
ReCell®, ReGenerCell™ and ReNovaCell™ are patented,
CE-marked for Europe. ReCell® is TGA-registered in Australia,
and CFDA-cleared in China. In the United States, ReCell® is an
investigational device limited by federal law to investigational
use, and a pivotal U.S. trial is well underway aimed at securing
FDA approval.

Avita Medical's unique proprietary technology enables a
clinician to rapidly create, at the point of care in approximately
30 minutes, Regenerative Epithelial Suspension (RES™) using a
small sample of the patient's skin. RES™ is an autologous
suspension comprising the cells and wound healing factors necessary
to regenerate natural, healthy skin. RES™ has a broad range
of applications and can be used to restart healing in unresponsive
wounds, to repair burns using less donor skin yet with improved
functional and aesthetic outcomes, and to restore pigmentation and
improve cosmesis of damaged skin.

Contact Profile

NewsMaker

NewsMaker is an Australian Press Release Distribution and Social Media Marketing service founded in 2004. The company today represents over 22,000 brands who seek to share their content with journalists, bloggers and the community.